EXTON, Pa., Feb. 5 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced that Vincent Milano, chief financial officer and chief operating officer of ViroPharma, will present at the BIO CEO & Investor Conference at 12:30 P.M. ET on Monday, February 11, 2008. The conference is being held at the Waldorf=Astoria, in New York.
ViroPharma’s presentation will be webcast live for investors through www.viropharma.com and available through February 28, 2008.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company’s website at www.viropharma.com.
CONTACT: William C. Roberts, Vice President, Corporate Communications,
+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,
+1-610-321-6290
Web site: http://www.viropharma.com/
